Search results
Author(s):
Felipe Martínez
Added:
4 years ago
In this video, Prof Felipe Martinez, Professor of Medicine (Córdoba National University, Córdoba, AR) discusses the design and rationale for DAPA-HF.
Filmed on site at ESC 2019 by Radcliffe Cardiology.
This interview is a component of a wider Radcliffe Education programme entitled,'Current and emerging data on SGLT2 inhibitors in heart failure'. Certified accreditation of the full programme is…
View more
Author(s):
Felipe Martínez
Added:
4 years ago
In this video, Prof Felipe Martinez, Professor of Medicine (Córdoba National University, Córdoba, AR) discusses the design and rationale for DAPA-HF.
Filmed on site at ESC 2019 by Radcliffe Cardiology.
This interview is a component of a wider Radcliffe Education programme entitled,'Current and emerging data on SGLT2 inhibitors in heart failure'. Certified accreditation of the full programme is…
View more
Author(s):
Harriette Van Spall
,
Mandeep Mehra
Added:
4 months ago
AHA 23 - Investigator, Dr Mandeep R Mehra (Brigham and Women's Hospital and Harvard Medical School, US) is joined by Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the ARIES HM3 trial.ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were…
View more
Author(s):
Harriette Van Spall
,
John Spertus
Added:
2 years ago
Late-breaker host Dr Harriette Van Spall (McMaster University, CA) invites PI, Dr John Spertus to discuss the innovative CHIEF-HF clinical trial.
The aim of this study was to determine the superiority of the effectiveness of canagliflozin versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score …
View more
Author(s):
Stephen Nicholls
Added:
2 years ago
In this video interview, Prof Stephen Nicholls (Victorian Heart Institute, Calyton, AU) shares the findings from the ROSE Clinical Trial. The placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluated the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy. Presented at AHA 2021, the study demonstrated that CETPi lowers LDL-C…
View more
Author(s):
Justin Ezekowitz
,
Harriette Van Spall
Added:
1 year ago
In this in-depth conversational interview, Late-breaker host Dr Harriette Van Spall(McMaster University, CA) meets PI, Dr Justin A. Ezekowitz (University of Alberta, CA) to discuss the SODIUM-HF trial (CT02012179). The aim of the trial was to evaluate the effects of a low-sodium diet, compared to usual care in patients with heart failure.
Presented first at ACC.22, the trial showed that reducing…
View more
Author(s):
Cindy Grines
,
Harriette Van Spall
Added:
2 years ago
In the second episode of theMasterclass video series, host, Dr Harriette Van Spall(McMaster University, Hamilton, CA) meets with Dr Cindy L Grines (Northside Hospital Cardiovascular Institute, Atlanta, GA, US), President of the Society for Cardiovascular Angiography and Interventions (SCAI).
Dr Van Spall and Dr Grines discuss gender-related inequities and the way forward in cardiology,…
View more
Evandro de Azambuja
Research Area(s) / Expertise:
Job title: Head of the Medical Support Team, Jules Bordet Insitute, Brussels, Belgium
Author
Author(s):
Faiez Zannad
Added:
1 year ago
ESC Congress 22 — Dr Faiez Zannad (University of Lorraine, FR) joins us onsite at ESC to provide an update on the EMPEROR-Pooled trial, a pooled analysis of the EMPEROR-Preserved and EMPEROR-Reduced studies which aimed to evaluate the effects of empagliflozin on patients with heart failure.
9718 patients with heart failure were pooled into the study, where it was found that the use of…
View more
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
1 year ago
Prof Nicolas Van Mieghem and Dr Joost Daemen return with their critical review series, View from the Thoraxcenter, to preview the most anticipated late-breaking and featured science trials of ACC.23.
Which trials have the potential to change practice? What are the key considerations for patient care and research? What is the context of the top trials of ACC?
Trials covered in detail include:
…
View more